Acadian Asset Management LLC Acquires 3,138 Shares of Becton, Dickinson and Company (NYSE:BDX)

Acadian Asset Management LLC raised its holdings in Becton, Dickinson and Company (NYSE:BDX) by 96.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 6,375 shares of the medical instruments supplier’s stock after acquiring an additional 3,138 shares during the quarter. Acadian Asset Management LLC’s holdings in Becton, Dickinson and Company were worth $1,489,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Hahn Capital Management LLC boosted its stake in Becton, Dickinson and Company by 33.2% in the second quarter. Hahn Capital Management LLC now owns 31,212 shares of the medical instruments supplier’s stock valued at $7,295,000 after acquiring an additional 7,782 shares during the last quarter. Chris Bulman Inc bought a new position in Becton, Dickinson and Company in the second quarter valued at approximately $54,000. Umpqua Bank boosted its stake in Becton, Dickinson and Company by 6.6% in the second quarter. Umpqua Bank now owns 2,689 shares of the medical instruments supplier’s stock valued at $628,000 after acquiring an additional 167 shares during the last quarter. Great Lakes Advisors LLC raised its holdings in Becton, Dickinson and Company by 3.3% in the second quarter. Great Lakes Advisors LLC now owns 229,621 shares of the medical instruments supplier’s stock worth $53,665,000 after purchasing an additional 7,282 shares during the period. Finally, Cullen Frost Bankers Inc. raised its holdings in Becton, Dickinson and Company by 1.2% in the second quarter. Cullen Frost Bankers Inc. now owns 6,049 shares of the medical instruments supplier’s stock worth $1,414,000 after purchasing an additional 69 shares during the period. 86.97% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on BDX. Raymond James cut their target price on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. The Goldman Sachs Group began coverage on shares of Becton, Dickinson and Company in a report on Thursday, May 30th. They issued a “buy” rating and a $274.00 target price on the stock. Citigroup cut their target price on shares of Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating on the stock in a report on Wednesday, July 10th. Finally, Evercore ISI dropped their price objective on shares of Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Moderate Buy” and an average target price of $279.50.

Becton, Dickinson and Company Stock Down 0.6 %

Shares of BDX stock opened at $234.18 on Monday. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $269.52. The firm’s fifty day moving average price is $234.71 and its two-hundred day moving average price is $235.61. The firm has a market capitalization of $67.69 billion, a P/E ratio of 51.58, a PEG ratio of 1.91 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The firm had revenue of $4.99 billion for the quarter, compared to analyst estimates of $5.08 billion. During the same period in the previous year, the business earned $2.96 EPS. The company’s revenue was up 2.3% compared to the same quarter last year. On average, equities analysts predict that Becton, Dickinson and Company will post 13.1 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be paid a $0.95 dividend. The ex-dividend date of this dividend is Monday, September 9th. This represents a $3.80 annualized dividend and a yield of 1.62%. Becton, Dickinson and Company’s payout ratio is currently 83.70%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.